Overview of the Therapeutic Potential of Aptamers Targeting Coagulation Factors
Aptamers are single-stranded DNA or RNA sequences that bind target molecules with high specificity and affinity. Aptamers exhibit several notable advantages over protein-based therapeutics. Aptamers are non-immunogenic, easier to synthesize and modify, and can bind targets with greater affinity. Due...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/8/3897 |
| _version_ | 1797538254206009344 |
|---|---|
| author | Max Liu Khalequz Zaman Yolanda M. Fortenberry |
| author_facet | Max Liu Khalequz Zaman Yolanda M. Fortenberry |
| author_sort | Max Liu |
| collection | DOAJ |
| description | Aptamers are single-stranded DNA or RNA sequences that bind target molecules with high specificity and affinity. Aptamers exhibit several notable advantages over protein-based therapeutics. Aptamers are non-immunogenic, easier to synthesize and modify, and can bind targets with greater affinity. Due to these benefits, aptamers are considered a promising therapeutic candidate to treat various conditions, including hematological disorders and cancer. An active area of research involves developing aptamers to target blood coagulation factors. These aptamers have the potential to treat cardiovascular diseases, blood disorders, and cancers. Although no aptamers targeting blood coagulation factors have been approved for clinical use, several aptamers have been evaluated in clinical trials and many more have demonstrated encouraging preclinical results. This review summarized our knowledge of the aptamers targeting proteins involved in coagulation, anticoagulation, fibrinolysis, their extensive applications as therapeutics and diagnostics tools, and the challenges they face for advancing to clinical use. |
| first_indexed | 2024-03-10T12:27:54Z |
| format | Article |
| id | doaj.art-507959948c6d433c9a04c0cb2dfc38a6 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T12:27:54Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-507959948c6d433c9a04c0cb2dfc38a62023-11-21T14:53:24ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-04-01228389710.3390/ijms22083897Overview of the Therapeutic Potential of Aptamers Targeting Coagulation FactorsMax Liu0Khalequz Zaman1Yolanda M. Fortenberry2Department of Biology, Case Western Reserve University, Cleveland, OH 44106, USADepartment of Biology, Case Western Reserve University, Cleveland, OH 44106, USADepartment of Biology, Case Western Reserve University, Cleveland, OH 44106, USAAptamers are single-stranded DNA or RNA sequences that bind target molecules with high specificity and affinity. Aptamers exhibit several notable advantages over protein-based therapeutics. Aptamers are non-immunogenic, easier to synthesize and modify, and can bind targets with greater affinity. Due to these benefits, aptamers are considered a promising therapeutic candidate to treat various conditions, including hematological disorders and cancer. An active area of research involves developing aptamers to target blood coagulation factors. These aptamers have the potential to treat cardiovascular diseases, blood disorders, and cancers. Although no aptamers targeting blood coagulation factors have been approved for clinical use, several aptamers have been evaluated in clinical trials and many more have demonstrated encouraging preclinical results. This review summarized our knowledge of the aptamers targeting proteins involved in coagulation, anticoagulation, fibrinolysis, their extensive applications as therapeutics and diagnostics tools, and the challenges they face for advancing to clinical use.https://www.mdpi.com/1422-0067/22/8/3897aptamersSELEXcoagulation factorsblood disordersprothrombinthrombin |
| spellingShingle | Max Liu Khalequz Zaman Yolanda M. Fortenberry Overview of the Therapeutic Potential of Aptamers Targeting Coagulation Factors International Journal of Molecular Sciences aptamers SELEX coagulation factors blood disorders prothrombin thrombin |
| title | Overview of the Therapeutic Potential of Aptamers Targeting Coagulation Factors |
| title_full | Overview of the Therapeutic Potential of Aptamers Targeting Coagulation Factors |
| title_fullStr | Overview of the Therapeutic Potential of Aptamers Targeting Coagulation Factors |
| title_full_unstemmed | Overview of the Therapeutic Potential of Aptamers Targeting Coagulation Factors |
| title_short | Overview of the Therapeutic Potential of Aptamers Targeting Coagulation Factors |
| title_sort | overview of the therapeutic potential of aptamers targeting coagulation factors |
| topic | aptamers SELEX coagulation factors blood disorders prothrombin thrombin |
| url | https://www.mdpi.com/1422-0067/22/8/3897 |
| work_keys_str_mv | AT maxliu overviewofthetherapeuticpotentialofaptamerstargetingcoagulationfactors AT khalequzzaman overviewofthetherapeuticpotentialofaptamerstargetingcoagulationfactors AT yolandamfortenberry overviewofthetherapeuticpotentialofaptamerstargetingcoagulationfactors |